Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 5/20 | 0.81 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | F2R | P25116 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11668137 | 0.91 | KCNK3 (0.84) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL3356211 | 0.85 | MEN1 (1.00) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL31424193 | 0.85 | MEN1 (0.72) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL16941525 | 0.85 | MEN1 (0.72) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL259352 | 0.85 | MEN1 (0.72) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL11305192 | 0.85 | KCNK3 (0.70) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL7181742 | 0.85 | MEN1 (0.71) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL14825240 | 0.84 | KCNK3 (0.82) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL21993 | 0.84 | HPGD (1.00) | KCNK3KCNK9KMT2AMEN1ALDH1A1 | |
| SCHEMBL19491367 | 0.84 | HPGD (0.78) | KCNK3KCNK9KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3395795-B1 | MALONONITRILE OXIME ETHER COMPOUND AND USE THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-10301318-B2 | Neuroactive compounds and methods of using the same | THE GENERAL HOSPITAL CORPORATION (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170247383-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| EP-2261215-B1 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMA CO LTD (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8647528-B2 | Water absorbing agent and production method thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8501730-B2 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8273735-B2 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120226034-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-06 | — | — | US | disclosed |
| EP-2251319-B1 | Process for preparing derivatives of benzoic acid | OTSUKA PHARMA CO LTD (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-1919874-B1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2261215-A1 | Process for preparing benzazepine compounds or salts thereof | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251319-A2 | Process for preparing derivatives of benzoic acid | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20100270501-A1 | Water absorbing agent and production method thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1919874-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026971-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| CN-1287046-C | Method for producing paper and yield-improving agent | SEIKO PMC CORP (JP) | 2006-11-29 | — | — | CN | disclosed |
| CN-1643215-A | Method for producing paper and yield-improving agent | SEIKO PMC CORP (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-4123554-A | Fungicidal and germicidal benzanilides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247383-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USING THE SAME | GAP43, PNMT, SLC6A3 | KCNK3 672/4885KCNK9 2152/4885KMT2A 492/4885 |
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | KCNK3 393/4885KCNK9 292/4885KMT2A 1587/4885 |
| US-20120226034-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | KCNK3 393/4885KCNK9 292/4885KMT2A 1587/4885 |
| US-10301318-B2 | Neuroactive compounds and methods of using the same | GAP43, PNMT, SLC6A3 | KCNK3 672/4885KCNK9 2152/4885KMT2A 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.